---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-039833"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T10:48:19.540387+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio raises $50M via registered direct offering, issues shares and warrants to institutional investors

## Summary
- Gross proceeds of ~$50M from sale of 14,072,615 shares and warrants; warrants could yield up to $60M more if fully exercised.
- Purchase price $3.5530 per share with accompanying warrant; warrant exercise price $4.2636, expires in 2 years.
- Jefferies LLC acts as exclusive placement agent; receives 6% cash fee on gross proceeds.
- Proceeds intended for working capital and ongoing business operations.
- Closing expected on or about February 17, 2023, subject to customary closing conditions.

## SEC filing metadata
- accession: 0001193125-23-039833
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/0001193125-23-039833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-039833
- JSON: https://secwatch.observer/filing/0001193125-23-039833.json
- Plain text: https://secwatch.observer/filing/0001193125-23-039833.txt

## Key facts
- Material Agreements
  ImmunityBio, Inc. entered into Stock Purchase Agreement with certain institutional investors valued at approximately $50.0 million (effective 2023-02-15).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $50.0 million
  - Effective: 2023-02-15
  source text: On February 15, 2023, ImmunityBio, Inc. (the “Company”) entered into a stock purchase agreement (the “SPA”) with certain institutional investors (the “Investors”) for the purchase and sale of 14,072,615 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase an additional 14,072,615 shares of Common Stock at an exercise price of $4.2636 per share, for a purchase price of $3.5530 per share and accompanying warrant, generating gross proceeds from the offering of approximately $50.0 million before deducting placement agent fees and other estimated offering expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/0001193125-23-039833-index.htm
- Material Agreements
  ImmunityBio, Inc. entered into Placement Agency Agreement with Jefferies LLC (effective 2023-02-15).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC
  - Effective: 2023-02-15
  source text: On February 15, 2023, the Company also entered into a placement agency agreement (the “PAA”) with Jefferies LLC (the “Placement Agent”). Pursuant to the terms of the PAA, the Placement Agent has agreed to serve as our exclusive Placement Agent on a reasonable best efforts basis to arrange for the sale of the securities described above and the Company has agreed to pay the Placement Agent a cash fee equal to 6.0% of the gross proceeds generated from the sale of such securities, less certain Company expenses to be reimbursed by the Placement Agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/0001193125-23-039833-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.